Igor Puzanov Archives
Cancer therapies’ impact on heart, kidneys explored
Sep. 24, 2015—Vanderbilt is embarking on a multi-disciplinary approach to understand how promising cancer treatments, specifically certain kinase inhibitors, affect the heart and kidneys.
New type of trial shows promise for several cancers
Aug. 20, 2015—Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation.
New targeted therapy shows promise for rare joint tumor
Aug. 6, 2015—Vanderbilt-Ingram Cancer Center (VICC) investigators and colleagues at several major medical centers have been testing a new targeted therapy that is showing promise for the treatment of a rare tumor that forms in and around joint cavities.
Indiana couple hits the links to support melanoma research
Oct. 16, 2014—A Vanderbilt-Ingram Cancer Center (VICC) melanoma patient is using his passion for golf to support melanoma research efforts at VICC.
VICC researchers in spotlight at national cancer conference
Jun. 19, 2014—New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.
Combined drug therapy may delay melanoma progression
Oct. 25, 2012—Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene.
